Hiroyoshi Kunimoto

Yokohama, 2360004, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.

Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.

Journal: Annals of hematology

Published: September 29, 2025

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia.

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia.

Journal: Scientific reports

Published: March 31, 2025

Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia.

Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia.

Journal: Haematologica

Published: December 24, 2024

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: December 13, 2024

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: December 13, 2024

Clonal Hematopoiesis in Chronic Thromboembolic Pulmonary Hypertension.

Clonal Hematopoiesis in Chronic Thromboembolic Pulmonary Hypertension.

Journal: Journal of the American Heart Association

Published: November 27, 2024

PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7.

PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7.

Journal: HemaSphere

Published: September 06, 2024

Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities.

Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities.

Journal: International journal of hematology

Published: September 04, 2024

Distinct features of trisomy 8-associated autoinflammatory disease from Behçet's disease: case series and systematic review.

Distinct features of trisomy 8-associated autoinflammatory disease from Behçet's disease: case series and systematic review.

Journal: Clinical and experimental rheumatology

Published: August 09, 2024

Rare severe constrictive pericarditis complication in Erdheim-Chester disease: A case report and literature review.

Rare severe constrictive pericarditis complication in Erdheim-Chester disease: A case report and literature review.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: July 31, 2024

Successful treatment of low-risk myelodysplastic syndrome-related anemia in patients with chronic kidney disease with daprodustat: A report of two cases.

Successful treatment of low-risk myelodysplastic syndrome-related anemia in patients with chronic kidney disease with daprodustat: A report of two cases.

Journal: EJHaem

Published: July 31, 2024

Epigenetic dysregulation and emerging treatment strategies in myelodysplastic syndromes

Epigenetic dysregulation and emerging treatment strategies in myelodysplastic syndromes

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: June 02, 2024

Showing 1-12 of 35

Last Updated: 09/26/2026